Which biomarkers actually catch risk decades early, and what do they reveal?

What cardiovascular biomarkers go beyond standard lipids?

Cardiovascular risk assessment has evolved substantially in recent years. The markers worth understanding:

• ApoB. Apolipoprotein B counts the actual atherogenic particles in circulation. More accurate than LDL-C alone, especially in people with insulin resistance, elevated triglycerides, or metabolic syndrome where LDL-C and ApoB diverge. The 2024 National Lipid Association Expert Consensus proposes stratified ApoB targets: under 90 mg/dL for intermediate-risk, under 70 mg/dL for high-risk, under 60 mg/dL for very high-risk patients [PMID: 39256087]
• Lp(a). Lipoprotein(a). Genetically determined, doesn't change much with lifestyle, an independent risk factor for cardiovascular disease and aortic stenosis. Elevated levels affect roughly 20% of the population at clinically significant levels. Worth measuring once in a lifetime. The 2024 NLA Update strongly endorses opportunistic or universal screening for Lp(a) in preventive cardiology [PMID: 38565461]
• LDL particle number and size. Small dense LDL particles are more atherogenic than large buoyant ones. Two people with the same LDL-C can have very different particle profiles
• Oxidized LDL. A marker of LDL that's undergone oxidative modification, more atherogenic than non-oxidized LDL
• hs-CRP. A general inflammatory marker associated with cardiovascular events. Optimal under 1.0 mg/L
• Homocysteine. Elevated values associated with cardiovascular and cognitive risk. Often responsive to B12, folate, and B6 optimization

What metabolic biomarkers catch dysfunction early?

Several metabolic markers reveal dysfunction years before standard testing would:

• Fasting insulin and HOMA-IR. Catches insulin resistance in its earliest stage, often years before any other marker shifts. Most adult metabolic dysfunction begins here
• Adiponectin. A marker of insulin sensitivity from fat tissue; lower levels indicate worse metabolic function
• Uric acid. Elevated values associated with insulin resistance, metabolic syndrome, gout, and cardiovascular risk
• Liver enzymes (ALT particularly). Often elevated early in metabolic dysfunction. ALT under 25 U/L is more optimal than the typical reference range floor of 40
• Continuous glucose monitoring data. Provides direct visualization of glucose patterns invisible to fasting tests

The pattern across these markers, particularly when fasting insulin and HOMA-IR are elevated alongside elevated triglycerides and a high triglyceride-to-HDL ratio, points toward early-stage metabolic dysfunction that's still highly reversible.

What inflammatory biomarkers matter?

Inflammation underlies most chronic disease. Useful inflammatory markers include:

• hs-CRP. General inflammation marker. Elevated values predict cardiovascular events and other disease. Optimal under 1.0 mg/L
• ESR (erythrocyte sedimentation rate). Less specific than hs-CRP but useful in some contexts
• Ferritin (when interpreted as an inflammatory marker rather than iron storage). Can be elevated in chronic inflammation
• Fibrinogen. Both an inflammatory marker and a clotting factor
• Cytokine panels. In some clinical contexts
• Omega-3 index. The percentage of EPA and DHA in red blood cell membranes. A marker of long-term anti-inflammatory fatty acid status. Optimal above 8%

A pattern of multiple elevated inflammatory markers points toward systemic inflammation that warrants investigation: chronic infection, autoimmune activity, gut dysfunction, dietary patterns, environmental exposures, or chronic stress.

What hormonal biomarkers reveal?

Beyond basic screening, comprehensive hormone assessment includes:

• Full thyroid panel: TSH (the brain's signal to the thyroid), free T4, free T3, reverse T3, TPO and thyroglobulin antibodies
• Sex hormones: estradiol, progesterone, total and free testosterone, SHBG (sex hormone binding globulin, which determines bioavailable hormone levels), DHEA-S
• IGF-1. A marker of growth hormone activity, relevant in some longevity contexts
• Comprehensive cortisol metabolite assessment measured across the day
• Melatonin in selected cases
• Prolactin, FSH, LH, AMH depending on clinical context

Standard hormone testing typically captures only TSH and maybe estradiol. The comprehensive panel reveals dysfunction that single-marker testing misses.

What nutrient biomarkers should be included?

Several nutrient markers have particular importance:

• Vitamin D (25-OH). Optimal 50 to 80 ng/mL for most adults; the lab reference floor of 30 is often inadequate
• B12 with methylmalonic acid. Catches functional B12 deficiency that serum B12 alone misses
• RBC magnesium. More accurate than serum magnesium, which is insensitive
• Iron studies with ferritin. Optimal ferritin 50 to 100+ ng/mL for energy support and hair growth, well above the lab's typical floor
• Omega-3 index. Optimal above 8%; many adults are below 4%
• Zinc, selenium, copper. Relevant in specific contexts

What is biological age testing?

Biological age testing aims to estimate cellular or physiological age, distinct from chronological age. Several methodologies exist:

• Epigenetic clocks based on DNA methylation patterns. The most validated approach. Different clocks (Horvath, Hannum, GrimAge, PhenoAge) measure different things and can give different results
• Telomere length assessment
• Glycan-based clocks and other emerging biomarkers

Biological age testing is most useful as a longitudinal tracking tool to assess intervention effectiveness over time, less useful as a single point estimate. The science is evolving; the field is still establishing which clocks are most clinically meaningful for which purposes.

The reasonable framing: biological age is an emerging area of measurement with promising validation but no single test that's the definitive answer. Tracking trends over time is more informative than any single number.

What genetic markers are clinically useful?

Several genetic tests have clear clinical utility:

• ApoE genotype. The strongest known genetic risk factor for late-onset Alzheimer's disease. A one-time test that informs cognitive risk stratification
• Cardiovascular genetic panels. Hereditary lipid disorders (familial hypercholesterolemia), Lp(a) genotype influencing levels
• Hereditary cancer panels. BRCA1/2, Lynch syndrome, broader multi-gene panels
• Pharmacogenomic testing. How the body metabolizes various medications, including many psychiatric drugs and blood thinners
• MTHFR variants. Relevant for folate and B12 metabolism in some interpretations, though clinical significance is debated and often overstated

Genetic results don't determine outcomes; they shape risk stratification and guide intervention strategy.

How do these biomarkers fit together?

Interpretation matters more than acquisition. Having advanced biomarker results without context produces confusion or inappropriate action. The clinical value comes from:

• Reading patterns across multiple markers, not single values
• Interpreting in the context of each other and the patient's full picture
• Identifying the dominant patterns
• Translating data into action

A pattern of elevated fasting insulin, elevated hs-CRP, elevated ApoB, low vitamin D, and a high triglyceride-to-HDL ratio tells a coherent story about metabolic syndrome that any single marker would miss. The synthesis is the work.

The deeper picture

Advanced biomarkers are increasingly accessible, but their value depends on interpretation. Reading the patterns across multiple markers, in the context of an individual's full picture, is where the clinical work lies. Extend integrates comprehensive biomarker assessment with clinical interpretation as part of precision medicine care.